[go: up one dir, main page]

WO2000032177A3 - Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections - Google Patents

Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections Download PDF

Info

Publication number
WO2000032177A3
WO2000032177A3 PCT/US1999/028082 US9928082W WO0032177A3 WO 2000032177 A3 WO2000032177 A3 WO 2000032177A3 US 9928082 W US9928082 W US 9928082W WO 0032177 A3 WO0032177 A3 WO 0032177A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
compounds
hepatitis
treatment
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/028082
Other languages
French (fr)
Other versions
WO2000032177A2 (en
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colthurst Ltd
Harbor Biosciences Inc
Original Assignee
Colthurst Ltd
Hollis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000584873A priority Critical patent/JP2002531397A/en
Priority to NZ511721A priority patent/NZ511721A/en
Priority to KR1020017006525A priority patent/KR20010101074A/en
Priority to CA002352205A priority patent/CA2352205A1/en
Priority to EP99965050A priority patent/EP1133287A2/en
Priority to BR9915644-0A priority patent/BR9915644A/en
Priority to APAP/P/2001/002181A priority patent/AP2001002181A0/en
Priority to HK02102267.0A priority patent/HK1042426A1/en
Application filed by Colthurst Ltd, Hollis Eden Pharmaceuticals Inc filed Critical Colthurst Ltd
Priority to IL14294299A priority patent/IL142942A0/en
Priority to AU31052/00A priority patent/AU775614B2/en
Publication of WO2000032177A2 publication Critical patent/WO2000032177A2/en
Publication of WO2000032177A3 publication Critical patent/WO2000032177A3/en
Priority to IL142942A priority patent/IL142942A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the 'compounds of the present invention', in the treatment of prevention of hepatitis C type virus and/or hepatitis G type virus in patients in need of such treatment. In addition, the invention provides methods to treat or prevent togavirus infections, including infections by one or more alphaviruses, flaviviruses, such as yellow fever virus, hepatitis C virus and hepatitis G virus, rubella viruses, or pestiviruses, such as bovine virus diarrhea virus. In addition, the invention provides combination therapies including administration of one or more compound of the present invention, as defined herein, and administration of one or more compound selected from plasma concentration-enhancing compounds, macrophage stimulating factor, oxidation agents, ribavirin and alpha interferon, and/or oxygen ventilation. The compounds of the present invention may also be used to ameliorate or reduce one or more symptoms associated with a togavirus infection.
PCT/US1999/028082 1998-11-24 1999-11-24 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections Ceased WO2000032177A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
APAP/P/2001/002181A AP2001002181A0 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
KR1020017006525A KR20010101074A (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
CA002352205A CA2352205A1 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
EP99965050A EP1133287A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids for the treatment of hepatitis c virus and other togaviruses
BR9915644-0A BR9915644A (en) 1998-11-24 1999-11-24 Use of 17-ketoesteroid compounds and their derivatives, metabolites and precursors in the treatment of hepatitis c virus and other togaviruses
HK02102267.0A HK1042426A1 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
IL14294299A IL142942A0 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses
JP2000584873A JP2002531397A (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and their derivatives, metabolites and precursors in the treatment of hepatitis C virus and other togaviruses
NZ511721A NZ511721A (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
AU31052/00A AU775614B2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
IL142942A IL142942A (en) 1998-11-24 2001-05-03 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof for manufacture of medicaments for use in the treatment of hepatitis c virus and other toga viruses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10992498P 1998-11-24 1998-11-24
US60/109,924 1998-11-24
US12408799P 1999-03-11 1999-03-11
US60/124,087 1999-03-11
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-03-23

Publications (2)

Publication Number Publication Date
WO2000032177A2 WO2000032177A2 (en) 2000-06-08
WO2000032177A3 true WO2000032177A3 (en) 2001-03-22

Family

ID=27380740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028082 Ceased WO2000032177A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections

Country Status (14)

Country Link
EP (1) EP1133287A2 (en)
JP (1) JP2002531397A (en)
KR (1) KR20010101074A (en)
CN (1) CN1328463A (en)
AP (1) AP2001002181A0 (en)
AU (1) AU775614B2 (en)
BR (1) BR9915644A (en)
CA (1) CA2352205A1 (en)
HK (1) HK1042426A1 (en)
ID (1) ID29864A (en)
IL (2) IL142942A0 (en)
NZ (1) NZ511721A (en)
OA (1) OA11716A (en)
WO (1) WO2000032177A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248115B2 (en) 2007-11-15 2016-02-02 Madaus Gmbh Silibinin component for the treatment of hepatitis

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1223928A2 (en) 1999-07-08 2002-07-24 Patrick Thomas Prendergast Use of flavones, coumarins and related compounds to treat infections
EP1228083A2 (en) 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
EP1534299A4 (en) * 2002-07-02 2007-04-11 Corcept Therapeutics Inc Methods for treating psychosis associated with interferon-alpha therapy
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
CN102993148B (en) * 2011-09-13 2015-12-09 复旦大学 Quercetin derivative or its analogue and application thereof
WO2013178782A1 (en) * 2012-05-30 2013-12-05 Universidad De Zaragoza Allosteric inhibitors of ns3 protease from hepatitis c virus
CN108003212A (en) * 2017-12-24 2018-05-08 扬州工业职业技术学院 A kind of dehydroepiandros-sterone -6- glucoside derivatives and its application as anti hepatitis C virus drug
CN111718392B (en) * 2019-07-25 2021-08-17 中国人民解放军海军军医大学 A class of tetracyclic triterpene acid derivatives and preparation method and application thereof
US20230355898A1 (en) * 2020-09-22 2023-11-09 Micronization Technologies And Therapeutics Group Llc Nebulizer and nebulized anti-virals

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956355A (en) * 1987-04-16 1990-09-11 Colthurst Limited Agents for the arrest and therapy of retroviral infections
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956355A (en) * 1987-04-16 1990-09-11 Colthurst Limited Agents for the arrest and therapy of retroviral infections
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. BEN-NATHAN: "Protection by dehydroepiandrosterone in mice infected with viral encephalitis", ARCH. VIROL., vol. 120, no. 3-4, 1991, pages 263 - 271, XP000922923 *
M.L. WOODS: "Treatment of aged mice with dehydroepiandrosterone provides an adjuvant effect in the immunization with recombinant hepatitis B surface antigen", J. IMMUNOL., vol. 150, no. 8 part 2, 1993, pages 77a, XP000915024 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248115B2 (en) 2007-11-15 2016-02-02 Madaus Gmbh Silibinin component for the treatment of hepatitis

Also Published As

Publication number Publication date
WO2000032177A2 (en) 2000-06-08
KR20010101074A (en) 2001-11-14
OA11716A (en) 2005-01-25
IL142942A0 (en) 2002-04-21
CA2352205A1 (en) 2000-06-08
JP2002531397A (en) 2002-09-24
AU3105200A (en) 2000-06-19
AU775614B2 (en) 2004-08-05
ID29864A (en) 2001-10-18
EP1133287A2 (en) 2001-09-19
BR9915644A (en) 2001-08-07
AP2001002181A0 (en) 2001-05-24
NZ511721A (en) 2004-07-30
CN1328463A (en) 2001-12-26
IL142942A (en) 2006-08-20
HK1042426A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
MXPA04012779A (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections.
MXPA02012443A (en) 3 -PRODRUGS OF 2 -DEOXY-bgr;-L-NUCLEOSIDES.
TW200500374A (en) 2' and 3' -nucleoside produrgs for treating flavivridae infections
AU2002360592A8 (en) Inhibitors of hepatitis c virus
WO2004002422A3 (en) 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PT1387681E (en) Use of castanospermine derivatives for the treatment of hepatitis c
AP1727A (en) Methods and compositions for treating flaviviruses and pestiviruses.
TWI317735B (en) Methods and compositions for treating hepatitis c virus
WO2000032177A3 (en) Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections
WO2005016288A3 (en) Methods and compositions for treatment of viral diseases
MY125300A (en) Synergistic combination for treatment of viral-mediated diseases
DE60125377D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE, INTERFERON AND RIBAVIRIN
AP2001002167A0 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis
SG153666A1 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813658.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 142942

Country of ref document: IL

Ref document number: 31052/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999965050

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/03847

Country of ref document: ZA

Ref document number: 200103847

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 511721

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2352205

Country of ref document: CA

Ref document number: 2352205

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005170

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 584873

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017006525

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999965050

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017006525

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 31052/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017006525

Country of ref document: KR